Partnered Liquid Tumor is under clinical development by Isogenica and currently in Phase II for Hematological Tumor. According to GlobalData, Phase II drugs for Hematological Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Partnered Liquid Tumor LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Partnered Liquid Tumor overview
Antibody is under development for the treatment of hematological tumor. The therapeutic candidate is being developed based on single domain antibody platform.
For a complete picture of Partnered Liquid Tumor’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.